Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity

Integrative Cancer Therapies

Volumn 4, Issue 2, 2005, Pages 110-130

  Conklin, Kenneth A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anthracyclines; Antioxidants; Breast cancer; Cancer; Cardiotoxicity; Coenzyme Q10; Doxorubicin; Mitochondria

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADRIAMYCINONE; ALDEHYDE DERIVATIVE; ALKENE DERIVATIVE; ALPHA TOCOPHEROL; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CARBONYL DERIVATIVE; CASPASE; CELL NUCLEUS DNA; COPPER; CREATINE KINASE; CREATINE PHOSPHATE; CYCLOPHOSPHAMIDE; CYTOCHROME A; CYTOCHROME B; CYTOCHROME C; CYTOCHROME C OXIDASE; CYTOCHROME C1; DAUNOMYCINONE; DAUNORUBICIN; DAUNORUBICINOL; DAUNOSAMINE; DIHYDROQUINONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; EPIRUBICIN; FLUOROURACIL; FREE RADICAL; GLUCURONIDE; HYDROGEN PEROXIDE; HYDROQUINONE; HYDROXYL RADICAL; IDARUBICIN; IRON; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; LYCOPENE; MALONALDEHYDE; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXYGEN; PEROXY RADICAL; POLYUNSATURATED FATTY ACID; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; RETINOL; RETINOL PALMITATE; SCAVENGER; SEMIQUINONE; SODIUM SELENITE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SULFATE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THYMINE DERIVATIVE; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VINCRISTINE; XANTHINE OXIDASE;

ACUTE TOXICITY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CELL DEATH; CELL PROTECTION; CELL REGENERATION; CELLULITIS; CHRONIC TOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTRON TRANSPORT; ENZYME ACTIVITY; HEART ARRHYTHMIA; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HISTOPATHOLOGY; HUMAN; LIPID PEROXIDATION; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATIVE STRESS; PANCYTOPENIA; PHARMACOKINETICS; PRIORITY JOURNAL; QT PROLONGATION; REDUCTION; RESPIRATORY CHAIN; TISSUE NECROSIS; WEIGHT GAIN;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CARDIOMYOPATHIES; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MITOCHONDRIA, HEART; NEOPLASMS; UBIQUINONE;

EID: 19544371393     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735405276191     Document Type: Article

References (207)

1. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60:1213-1218.
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
3. Choe JY, Combs AB, Folkers K. Prevention bycoenzyme Q10 of the electrocardiographic changes induced by Adriamycin in rats. Res Commun Chem Path Pharmacol. 1979;23:199-202.
4. Folkers K, Choe JY, Combs AB. Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of Adriamycin in the rat. Proc Natl Acad Sci U S A. 1978;75:5178-5180.
5. Zbinden G, Bachmann E, Bolliger H. Study of coenzyme Q in toxicity of Adriamycin. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1977:219-228.
6. Furukawa K, Furukawa K, Yamasaki Y, Katsume H, Kitamura K, Ijichi H. The restorative effect of coenzyme Q10 on the Adriamycin-induced depression of myocardial contractility. In: Yamamura Y, Folkers K, Ito Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1980:225-230.
7. Ohhara H, Kanaide H, Nakamura M. A protective effect of coenzyme Q10 on the Adriamycin-induced cardiotoxicity in the isolated perfused rat heart. J Mol Cell Cardiol. 1981;13:741-752.
8. Ronca-Testoni S, Zucchi R, Ronca F, Bertelli A. Effect of carnitine and coenzyme Q10 on the calcium uptake in heart sarcoplasmic reticulum of rats treated with anthracyclines. Drugs Exp Clin Res. 1992;18:437-442.
9. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-1118.
10. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
11. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med. 1977;62:200-208.
12. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc. 1991;266:1672-1677.
13. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24:352-361.
14. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
15. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865-872.
16. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973;32:771-778.
17. Gandin PB, Hruban RH, Beschorner WE, et al. Myocarditis associated with doxorubicin cardiotoxicity. Am J Clin Pathol. 1993;100:158-163.
18. Ainger LE, Bushore J, Johnson WW, Ito J. Daunomycin: a cardiotoxic agent. J Natl Med Assoc. 1971;63:261-267.
19. Jaenke RS. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 1974;30:292-304.
20. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and morphologic alterations of myocardium in Adriamycin-treated rabbits. Am J Pathol. 1974;77:439-454.
21. Usui T, Ishikura H, Izumi Y, et al. Possible prevention from the progression of cardiotoxicity in Adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett. 1982;12:75-82.
22. Domae N, Sawada H, Matsuyama E, Konishi T, Uchino H. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat Rep. 1981;65:79-91.
23. Van Vleet JF, Greenwood L, Ferrans VJ, Rebar AH. Effect of selenium-vitamin E on Adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res. 1978;39:997-1010.
24. Breed JGS, Zimmerman ANE, Dormans JAMA, Pinedo HM. Failure of the antioxidant vitamin E to protect against Adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 1980;40:2033-2038.
25. Olson HM, Capen CC. Subacute cardiotoxicity of Adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest. 1977;37:386-394.
26. Neri GC, Neri B, Bandinelli M, Del Tacca M, Danesi R, Riccardi R. Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat. Oncology. 1991;48:327-333.
27. Aversano RC, Boor PJ. Histochemical alterations of acute and chronic doxorubicin cardiotoxicity. J Mol Cell Cardiol. 1983;15:543-553.
28. Lambertenghi-Deliliers G, Zanon PL, Pozzoli EF, Bellini O. Myocardial injury induced by a single dose of Adriamycin: an electron microscopic study. Tumori. 1976;62:517-528.
29. Rosenoff SH, Olson HM, Young DM, Bostick F, Young RC. Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst. 1975;55:191-194.
30. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52:194-201.
31. Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS. Structural and functional impairment of mitochondria in Adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem Pharmacol. 1999;57:481-489.
32. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-777.
33. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenals, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
34. Milei J, Boveris A, Llesuy S, et al. Amelioration of Adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J. 1986;111:95-102.
35. Lenzhofer R, Magometschnigg D, Dudczak R, Cerni C, Bolebruch C, Moser K. Indication of reduced doxorubicin-induced cardiac toxicity by additional treatment with antioxidative substances. Experentia. 1983;39:62-64.
36. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-167.
37. Fujita K, Shinpo K, Yamada K, et al. Reduction of Adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res. 1982;42:309-316.
38. Luo X, Evrovsky Y, Cole D, Trines J, Benson LN, Lehotay DC. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochim Biophys Acta. 1997;1360:45-52.
39. Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001;121:151-157.
40. Adachi K, Fujiura Y, Mayumi F, et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun. 1993;195:945-951.
41. Shinozawa S, Etowo K, Araki Y, Oda T. Effect of coenzyme Q10 on the survival time and lipid peroxidation of Adriamycin (doxorubicin) treated mice. Acta Med Okayama. 1984;38:57-63.
42. Shinozawa S, Gomita Y, Araki Y. Protective effects of various drugs on Adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharmacol Bull. 1993;16:1114-1117.
43. Yamanaka N, Kato T, Nishida K, Fujikawa T, Fukushima M, Ota K. Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-α-tocopherol acetate or coenzyme Q10 in mouse. Cancer Chemother Pharmacol. 1979;3:223-227.
44. Yamanaka N, Kato T, Nishida K, Fujikawa T, Fukushima M, Ota K. Protective effect of coenzyme Q10 on Adriamycin toxicity and increase of antitumor effects of Adriamycin by coenzyme Q10. In: Yamamura Y, Folkers K, Ito Y, eds. Biomedical and Clinical Aspects of Coenzyme. Q. Vol 2. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1980:213-224.
45. Faber M, Coudray C, Hida H, Mousseau M, Favier A. Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy including Adriamycin: a preliminary study. Biol Trace Elem Res. 1995;47:117-123.
46. Erhola M, Kellokumpu-Lehtinen P, Metsa-Ketela T, Alanko K, Nieminen MM. Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. Free Radic Biol Med. 1996;21:383-390.
47. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med. 1990;8:15-19.
48. Faure H, Coudray C, Mousseau M, et al. 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in Adriamycin-treated patients. Free Radic Biol Med. 1996;20:979-983.
49. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (Adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47:219-231.
50. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation. Cancer Res. 1983;43:460-472.
51. Nohl H, Jordan W. OH-generation by Adriamycin semiquinone and H2O2; an explanation for the cardiotoxicity of anthracycline antibiotics. Biochem Biophys Res Commun. 1983;114:197-205.
52. Goodman J, Hochstein P. Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and Daunomycin. Biochem Biophys Res Commun. 1977;77:797-803.
53. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A. 1979;76:954-957.
54. Solaini G, Landi L, Pasquali P, Rossi CA. Protective effect of endogenous coenzyme Q on both lipid peroxidation and respiratory chain inactivation induced by an Adriamycin-iron complex. Biochem Biophys Res Commun. 1987;147:572-580.
55. Takahashi K, Mayumi T, Kishi T. Evidence that lipid peroxidation by doxorubicin does not initiate the beat inhibition of cultured mouse myocardial cells. Chem Pharmacol Bull. 1987;35:4626-4631.
56. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988;48:4766-4769.
57. Boxer GE, Devlin TM. Pathways of intracellular hydrogen transport: absence of enzymatic hydrogen-carrying systems is a factor in aerobic glycolysis of malignant tissue. Science. 1961;134:1495-1501.
58. Borst P. The aerobic oxidation of reduced diphosphopyridine nucleotide formed by glycolysis in Ehrlich ascites-tumor cells. Biochim Biophys Acta. 1962;57:270-282.
59. Lehninger AL. Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide. J Biol Chem. 1951;190:345-359.
60. Rasmussen UF, Rasmussen HN. The NADH oxidase system (external) of muscle mitochondria and its role in the oxidation of cytoplasmic NADH. Biochem J. 1985;229:632-641.
61. Nohl H. Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. Eur J Biochem. 1987;169:585-591.
62. Davies KJA, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria: I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261:3060-3067.
63. Doroshow JH, Davies KJA. Redox cycling of anthracyclines by cardiac mitochondria: II. Formation of Superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261:3068-3074.
64. Nohl H. Identification of the site of Adriamycin-activation in the heart cell. Biochem Pharmacol. 1988;37:2633-2637.
65. Gille L, Nohl H. Analyses of the molecular mechanism of Adriamycin-induced cardiotoxicity. Free Radic Biol Med. 1997;23:775-782.
66. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by Adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. Proc Natl Acad Sci U S A. 1976;73:4653-4656.
67. Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta. 2000;302:1-9.
68. Karlsson J, Folkers K, Astrom H, et al. Effect of Adriamycin on heart and skeletal muscle coenzyme Q10 (CoQ10) in man. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1986:241-245.
69. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta. 1997;1321:101-106.
70. Serrano J, Palmeira CM, Kuehl DW, Wallace KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta. 1999;1411:201-205.
71. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997;94:514-519.
72. Singh G, Sharkey SM, Moorehead R. Mitochondrial DNA damage by anticancer agents. Pharmacol Ther. 1992;54:217-230.
73. Papadopoulou LC, Tsiftsoglou AS. Effects of hemin on apoptosis, suppression of cytochrome C oxidase gene expression, and bone-marrow toxicity induced by doxorubicin. Biochem Pharmacol. 1996;52:713-722.
74. Ozawa T, Tanaka M, Sugiyama S, et al. Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertorphic or dilated cardiomyopathy. Biochem Biophys Res Commun. 1990;170:830-836.
75. Battino M, Ferri E, Gorini A, et al. Natural distribution and occurrence of coenzyme Q homologues. Membr Biochem. 1990;9:179-190.
76. Ramasarma T. Natural occurrence and distribution of coenzyme Q. In: Lenaz G, ed. Coenzyme Q: Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. Chichester, UK: John Wiley & Sons; 1985:67-81.
77. Ramasarma T. Metabolism of coenzyme Q. In: Lenaz G, ed. Coenzyme Q: Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. Chichester, UK: John Wiley & Sons; 1985:131-142.
78. Rauchova H, Drahota Z, Lenaz G. Function of coenzyme Qin the cell: some biochemical and physiological properties. Physiol Res. 1995;44:209-216.
79. Ernster L, Forsmark-Andree P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Invest. 1993;71:S60-S65.
80. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A. 1990;87:4879-4883.
81. Ozawa T. Formation of oxygen radicals in the electron transfer chain and antioxidant properties of coenzyme Q. In: Lenaz G, ed. Coenzyme Q: Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. Chichester, UK: John Wiley & Sons; 1985:441-456.
82. Niki E. Mechanisms and dynamics of antioxidant action of ubiquinol. Mol Aspects Med. 1997;18:s63-s70.
83. Crane FL, Navas P. The diversity of coenzyme Q function. Mol Aspects Med. 1997;18:s1-s6.
84. Constantinescu A, Maguire JJ, Packer L. Interactions between ubiquinones and vitamins in membranes and cells. Mol Aspects Med. 1994;15:s57-s65.
85. Sugiyama S, Kitazawa M, Ozawa T, Suzuki K, Izawa Y. Anti-oxidative effect of coenzyme Q10. Experientia. 1980;36:1002-1003.
86. Forsmark-Andree P, Ernster L. Evidence for a protective effect of endogenous ubiquinol against oxidative damage to mitochondrial protein and DNA during lipid peroxidation. Mol Aspects Med. 1994;15:s73-s81.
87. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992;1126:247-254.
88. Kontush A, Hubner C, Finckh B, Kohlschutter A, Beisiegel U. Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density lipoprotein. Biochim Biophys Acta. 1995;1258:177-187.
89. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc Natl Acad Sci U S A. 1991;88:1646-1650.
90. Weber C, Jakobsen TS, Mortensen SA, Paulsen G, Holmer G. Effect of dietary coenzyme Q10 as an antioxidant in human plasma. Mol Aspects Med. 1994;15:s97-s102.
91. Kalen A, Norling B, Appelkvist EL, Dallner G. Ubiquinone biosynthesis by the microsomal fraction from rat liver. Biochim Biophys Acta. 1987;926:70-78.
92. Kishi H, Kanamori N, Nishii S, Hiraoka E, Okamoto T, Kishi T. Metabolism of exogenous coenzyme Q10 in vivo and the bioavailability of coenzyme Q10 preparations in Japan. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1984:131-142.
93. Jayaraman J, Joshi VC, Ramasarma T. Some aspects of the metabolism of coenzyme Q in the rat. Biochem J. 1963;88:369-373.
94. Nobuyoshi M, Saito T, Takahira H, Yamano Y, Kanazawa T. Levels of coenzyme Q10 in biopsies of left ventricular muscle and influence of administration of coenzyme Q10. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q Vol 4. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1984:221-229.
95. Nakamura T, Sanma H, Himeno M, Kato K. Transfer of exogenous coenzyme Q10 to the inner membrane of heart mitochondria in rats. In: Yamamura Y, Folkers K, Ito Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1980:3-14.
96. Weber C, Bysted A, Holmer G. Coenzyme Q10 in the diet-daily intake and relative bioavailability. Mol Aspects Med. 1997;18:s251-s254.
97. Hallstrom H. Oskadlighetsbedomning av coenzym Q10. Var Foda. 1993;45:250-259.
98. Kishi T, Okamoto T, Kanamori N, et al. Estimation of plasma levels of coenzyme Q10 and relationship to oral dosage. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 3. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1981:67-78.
99. Weber C, Bysted A, Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutr Res. 1997;17:941-945.
100. Folkers K, Moesgaard S, Morita M. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol Aspects Med. 1994;15:s281-s285.
101. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997;234:296-299.
102. Weis M, Mortensen SA, Rassing MR, Moller-Sonnergaard J, Poulsen G, Rasmussen SN. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med. 1994;15:s273-s280.
103. Bogentoft C, Edlund PO, Olsson B, Widlund L, Westensen K. Biopharmaceutical aspects of intravenous and oral administration of coenzyme Q10. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 6. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1991:215-224.
104. Lucker PW, Wetzelsberger N, Hennings G, Rehn D. Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1984:143-151.
105. Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. Pharmacokinetic study of deuterium-labeled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol. 1986;24:536-541.
106. Speth PAJ, Linssen PCM, Holdrinet RSG, Haanen C. Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin Pharmacol Ther. 1987;41:661-665.
107. Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C. Cellular and plasma Adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother Pharmacol. 1987;20:305-310.
108. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of Adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 1983;43:3417-3421.
109. Bronchud MH, Margison JM, Howell A, Lind M, Lucas SB, Wilkinson PM. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1990;25:435-439.
110. Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol. 1987;20:311-315.
111. Benjamin RS, Riggs CE Jr, Bachur NR. Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977;37:1416-1420.
112. Alberts DS, Bachur NR, Holtzman JL. The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther. 1971;12:96-104.
113. Lee Y-TN, Chan KK, Harris PA, Cohen JL. Distribution of Adriamycin in cancer patients: tissue uptakes, plasma concentrations after IV and hepatic IA administration. Cancer. 1980;45:2231-2239.
114. Cummings J, McArdle CS. Studies on the in vivo disposition of Adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer. 1986;53:835-838.
115. Duffy PM, Hayes MC, Gatrell SKE, Cooper A, Smart CJ. Determination and reversal of resistance to epirubicin intravesical chemotherapy: a confocal imaging study. Br J Urol. 1996;77:824-829.
116. Coley HM, Amos WB, Twentyman PR, Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer. 1993;67:1316-1323.
117. Jennings AM, Solomon LZ, Sharpe P, Hayes MC, Cooper AJ, Birch BR. Estramustine reversal of resistance to intravesical epirubicin chemotherapy. Eur Urol. 1999;35:327-335.
118. Davies CL, Loizidou M, Cooper AJ, Taylor I. Effect of γ-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. Eur J Cancer. 1999;35:1534-1540.
119. Burns CP, North JA, Petersen ES, Ingraham LM. Subcellular distribution of doxorubicin: comparison of fatty acid-modified and unmodified cells. Proc Soc Exp Biol Med. 1988;188:455-460.
120. Gigli M, Doglia SM, Millot JM, Valentini L, Manfait M. Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. Biochim Biophys Acta. 1988;950:13-20.
121. Takanashi S, Bachur NR, Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab Dispos. 1976;4:79-87.
122. Bachur NR, Steele M, Meriwether WD, Hildebrand RC. Cellular pharmacodynamics of several anthracycline antibiotics. J Med Chem. 1976;19:651-654.
123. Iwamoto Y, Hansen IL, Porter TH, Folkers K. Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by Adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun. 1974;58:633-638.
124. Muhammed H, Kurup CKR. Influence of ubiquinone on the inhibitory effect of Adriamycin on mitochondrial oxidative phosphorylation. Biochem J. 1984;217:493-498.
125. Solaini G, Ronca G, Bertelli A. Inhibitory effect of several anthracyclines on mitochondrial respiration and coenzyme Q10 protection. Drugs Exp Clin Res. 1985;11:533-537.
126. Kishi T, Kishi H, Folkers K. Inhibition of cardiac CoQ10-enzymes by clinically used drugs and possible prevention. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1977:47-62.
127. Folkers K, Lin M, Watanabe T, Porter TH. Inhibition by Adriamycin of the mitochondrial biosynthesis of coenzyme Q10 and implication for the cardiotoxicity of Adriamycin in cancer patients. Biochem Biophys Res Commun. 1977;77:1536-1542.
128. Takahashi K, Mayumi T, Kishi T. Influence of coenzyme Q10 on doxorubicin uptake and metabolism by mouse myocardial cells in culture. Chem Pharmacol Bull. 1988;36:1514-1518.
129. Kishi T, Takahashi K, Mayumi T, Hama T. Protective effect of coenzyme Q10 on Adriamycin toxicity in beating heart cells. In: Folkers K, Yamamura Y. eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1984:181-194.
130. Okamoto K, Ogura R. Effects of vitamins on lipid peroxidation and suppression of DNA synthesis induced by Adriamycin in Ehrlich cells. J Nutr Sci Vitaminol. 1985;31:129-137.
131. Bartoli GM, Galeotti T. Growth-related lipid peroxidation in tumour microsomal membranes and mitochondria. Biochim Biophys Acta. 1979;574:537-541.
132. Lash ED. The antioxidant and prooxidant activity in ascites tumors. Arch Biochem Biophys. 1966;115:332-336.
133. Gravela E, Feo F, Canuto RA, Garcea R, Gabriel L. Functional and structural alterations of liver ergastoplasmic membranes during DL-ethionine hepatocarcinogenesis. Cancer Res. 1975;35:3041-3047.
134. Cheeseman KH, Collins M, Proudfoot K, et al. Studies on lipid peroxidation in normal and tumour tissues. The Novikoff rat liver tumour. Biochem J. 1986;235:507-514.
135. Cheeseman KH, Emery S, Maddix SP, Slater TF, Burton GW, Ingold KU. Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour. Biochem J. 1988;250:247-252.
136. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res. 1978;22:190-274.
137. Utsumi K, Yamamoto G, Inaba K. Failure of Fe2+-induced lipid peroxidation and swelling in the mitochondria isolated from ascites tumor cells. Biochim Biophys Acta. 1965;105:368-371.
138. Player TJ, Mills DJ, Horton AA. Lipid peroxidation of the microsomal fraction and extracted microsomal lipids from DAB-induced hepatomas. Br J Cancer. 1979;39:773-778.
139. Kayawake S, Nakanishi T, Furukawa K, et al. The protective effect of coenzyme Q10 upon the jeopardized myocardium. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1984:173-179.
140. Ghione M, Bertazzoli C. CoQ and anthracycline associated cardiomyopathy. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1977:183-199.
141. Neri B, Neri GC, Bandinelli M. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. Oncology. 1988;45:242-246.
142. Combs AB, Choe JY, Truong DH, Folkers K. Reduction by coenzyme Q10 of the acute toxicity of Adriamycin in mice. Res Commun Chem Pathol Pharmacol. 1977;18:565-568.
143. Lubawy WC, Whaley J, Hurley LH. Coenzyme Q10 or α-tocopherol reduce the acute toxicity of anthramycin in mice. Res Commun Chem Pathol Pharmacol. 1979;24:401-404.
144. Shaeffer J, El-Mahdi AM, Nichols RK. Coenzyme Q10 and Adriamycin toxicity in mice. Res Commun Chem Pathol Pharmacol. 1980;29:309-315.
145. Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of α-tocopherol on the toxicity, disposition, and metabolism of Adriamycin in mice. Toxicol Appl Pharmacol. 1979;49:119-126.
146. Myers CE, McGuire W, Young R. Adriamycin: amelioration of toxicity by α-tocopherol. Cancer Treat Rep. 1976;60:961-962.
147. Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and Adriamycin toxicity. Am J Clin Nutr. 1991;54:1298S-1301S.
148. Shinozawa S, Gomita Y, Araki Y. Protection against Adriamycin (doxorubicin)-induced toxicity in mice by several clinically used drugs. Acta Med Okayama. 1987;41:11-17.
149. Tesoriere L, Ciaccio M, Valenza M, et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther. 1994;269:430-436.
150. Wang YM, Madanat FF, Kimball JC, et al. Effect of vitamin E against Adriamycin-induced toxicity in rabbits. Cancer Res. 1980;40:1022-1027.
151. Sawada H, Dohmae N, Tashima M, et al. Chronic cardiotoxicity of Adriamycin and possible prevention by coenzyme Q10 in rabbits. In: Yamamura Y, Folkers K, Ito Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1980:189-204.
152. Sugiyama S, Yamada K, Hayakawa M, Ozawa T. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts: liposome-encapsulated doxorubicin or combination therapy with antioxidants. Biochem Mol Biol Int. 1995;36:1001-1007.
153. Van Vleet JF, Ferrans VJ. Evaluation of vitamin E and selenium protection against chronic Adriamycin toxicity in rabbits. Cancer Treat Rep. 1980;64:315-317.
154. Van Vleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 1980;99:13-24.
155. Judy WV, Hall JH, Dugan W, Toth PD, Folkers K. Coenzyme Q10 reduction of Adriamycin cardiotoxicity. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1984:231-241.
156. Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep. 1978;62:887-891.
157. Cortes EP, Gupta M, Chou C, Patel M, Mundia A, Folkers K. Study of administration of coenzyme Q10 to Adriamycin treated cancer patients. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1977:267-278.
158. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15:s207-s212.
159. Folkers K, Baker L, Richardson PC, et al. Biomedical and clinical research on coenzyme Q10. In: Yamamura Y, Folkers K, Ito Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1980:447-454.
160. Folkers K, Baker L, Richardson PC, et al. New progress on the biomedical and clinical research on coenzyme Q10. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 3. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1981:399-412.
161. Okuma K, Ota K. The effect of coenzyme Q10 on ECG changes induced by doxorubicin (Adriamycin). In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Amsterdam, the Netherlands: Elsevier/North-Holland Biomedical Press; 1986:247-256.
162. Takimoto M, Sakurai T, Kodama K, et al. Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy. Gan To Kagaku Ryoho. 1982;9:116-121.
163. Tsubaki K, Horiuchi A, Kitani T, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. Gan To Kagaku Ryoho. 1984;11:1420-1427.
164. Yamamura Y. A survey of the therapeutic uses of coenzyme Q. In: Lenaz. G, ed. Coenzyme Q: Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. Chichester. UK: John Wiley & Sons; 1985:479-505.
165. Legha SS, Wang YM, Mackay B, et al. Clinical and pharmacologic investigation of the effects of α-tocopherol on Adriamycin cardiotoxicity. Ann N Y Acad Sci, 1982;393:411-418.
166. Weitzman SA, Lorell B, Carey RW, Kaufman S, Stossel TP. Prospective study of tocopherol prophylaxis for anthracycline cardiac oxicity. Curr Ther Res. 1980;28:682-686.
167. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727-741.
168. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997;11:931-935.
169. Rowley DA, Halliwell B. DNA damage by superoxide-generating systems in relation to the mechanism of action of the anti-tumor antibiotic Adriamycin. Biochim Biophys Acta. 1983;761:86-93.
170. Potmesil M, Kirschenbaum S, Israel M, Levin M, Khetarpal VK, Silber R. Relationship of Adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. Cancer Res. 1983;43:3528-3533.
171. Alegria AE, Samuni A, Mitchell JB, Riesz P, Russo A. Free radicals induced by Adriamycin-sensitive and Adriamycin-resistant cells: a spin-trapping study. Biochemistry. 1989;28:8653-8658.
172. Meijer C, Mulder NH, Timmer-Bosscha H, Zijlstra JG, de Vries EGE. Role of free radicals in an Adriamycin-resistant human small cell lung cancer cell line. Cancer Res. 1987;47:4613-4617.
173. Prasad KN, Edwards-Prasad J, Ramanujam S, Sakamoto A. Vitamin E increases the growth inhibitory and differentiating effects of tumor therapeutic agents on neuroblastoma and glioma cells in culture. Proc Soc Exp Biol Med. 1980;164:158-163.
174. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21 WAF1/CIP1 via C/EBPβ. Nat Med. 1997;3:1233-1241.
175. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996;103:183-189.
176. Ciaccio M, Tesoriere L, Pintaudi AM, et al. Vitamin A preserves the cytotoxic activity of Adriamycin while counteracting its peroxidative effects in human leukemic cells in vitro. Biochem Mol Biol Int. 1994;34:329-335.
177. Wahab MHA, Akoul E-SEMS, Abdel Aziz A-AH. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Tumori. 2000;86:157-162.
178. Sonneveld P. Effect of α-tocopherol on the cardiotoxicity of Adriamycin in the rat. Cancer Treat Rep. 1978;62:1033-1036.
179. Nesbitt JA, Smith J, McDowell G, Drago JR. Adriamycin-vitamin E combination therapy for treatment of prostate adenocarcinoma in the Nb rat model. J Surg Oncol. 1988;38:283-284.
180. Taper HS, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer. 1987;40:575-579.
181. Nakagawa M, Yamaguchi T, Ueda H, et al. Potentiation by vitamin A of the action of anticancer agents against murine tumors. Jpn J Cancer Res. 1985;76:887-894.
182. Teicher BA, Schwartz JL, Holden SA, Ara G, Northey D. In vivo modulation of several anticancer agents by β-carotene. Cancer Chemother Pharmacol 1994;34:235-241.
183. Alberts DS, Peng YM, Moon TE. α-Tocopherol pretreatment increases Adriamycin bone marrow toxicity. Biomedicine. 1978;29:189-191.
184. Akihama T, Nakamoto Y, Shindo T, Nakayama Y, Miura A. Protective effects of coenzyme Q10 on the adverse reactions of anthracycline antibiotics: using double blind method-with special reference to hair loss. Can To Kagaku Ryoho. 1983;10:2125-2129.
185. Dianzani MU. Lipid peroxidation and cancer. Crit Rev Oncol Hematol 1993;15:125-147.
186. Hauptlorenz S, Esterbauer H, Moll W, Pumpel R, Schauenstein E, Puschendorf B. Effects of the lipidperoxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochem Pharmacol. 1985;34:3803-3809.
187. Gonzalez MJ. Lipid peroxidation and tumor growth: an inverse relationship. Mod Hypotheses. 1992;38:106-110.
188. Schackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med. 2000;28:1387-1404.
189. Balin AK, Goodman DBP, Rasmussen H, Cristofalo VJ. Oxygen-sensitive stages of the cell cycle of human diploid cells. J Cell Biol. 1978;78:390-400.
190. Kurata S. Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. J Biol Chem. 2000;275:23413-23416.
191. Liepkalns VA, Icard-Liepkalns C, Cornwell DG. Regulation of cell division in a human glioma cell clone by arachidonic acid and α-tocopherolquinone. Cancer Lett. 1982;15:173-178.
192. Chajes V, Sattler W, Stranzl A, Kostner GM. Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin-E. Breast Cancer Res Treat. 1995;34:199-212.
193. Masotti L, Casali E, Galeotti T. Lipid peroxidation in tumor cells. Free Radic Biol Med. 1988;4:377-386.
194. Gonzalez MJ, Schemmel RA, Gray JI, Dugan L, Sheffield LG, Welsch CW. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis. 1991;12:1231-1235.
195. Gonzalez MJ, Schemmel RA, Dugan L, Gray JI, Welsch CW. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids. 1993;28:827-832.
196. Shao Y, Pardini L, Pardini RS. Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids. 1995;30:1035-1045.
197. Bartoli GM, Galeotti T. Growth-related lipid peroxidation in tumour microsomal membranes and mitochondria. Biochim Biophys Acta. 1979;574:537-541.
198. Barrera G, DiMauro C, Muraca R, et al. Induction of differentiation in human HL-60 cells by 4-hydroxynonenol, a product of lipid peroxidation. Exp Cell Res. 1991;197:148-152.
199. Tessitore L, Bonelli G, Costelli P, et al. Effect of two aliphatic aldehydes, methylglyoxal and 4-hydroxypentenal, on the growth of Yoshida ascites hepatoma AH-130. Chem Biol Interact. 1989;70:227-240.
200. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry. 1986;25:2248-2256.
201. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res. 1987;47:3973-3979.
202. Shacter E, Williams JA, Hinson RM, Senturker S, Lee YJ. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood. 2000;96:307-313.
203. Lee Y-J, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. Biol Chem. 1999;274:19792-19798.
204. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med. 2000;29:323-333.
205. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett. 1997;414:552-556.
206. Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci. 1998;854:328-335.
207. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3:294-300.